Phil J Borman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5622463/publications.pdf

Version: 2024-02-01

686830 752256 20 465 13 20 h-index citations g-index papers 21 21 21 384 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Toward Single-Calibrant Quantification in HPLC. A Comparison of Three Detection Strategies:Â Evaporative Light Scattering, Chemiluminescent Nitrogen, and Proton NMR. Analytical Chemistry, 2005, 77, 4354-4365.	3.2	85
2	Using the Analytical Target Profile to Drive the Analytical Method Lifecycle. Analytical Chemistry, 2019, 91, 2577-2585.	3.2	61
3	Design and Analysis of Method Equivalence Studies. Analytical Chemistry, 2009, 81, 9849-9857.	3.2	41
4	Comparative performances of selected chiral HPLC, SFC, and CE systems with a chemically diverse sample set. Chirality, 2003, 15, S1-S12.	1.3	38
5	Acceptance Criteria for Method Equivalency Assessments. Analytical Chemistry, 2009, 81, 9841-9848.	3.2	37
6	Method ruggedness studies incorporating a risk based approach: A tutorial. Analytica Chimica Acta, 2011, 703, 101-113.	2.6	33
7	Rapid Determination of Enantiomeric Excess Using Infrared Thermography. Organic Process Research and Development, 2002, 6, 463-470.	1.3	25
8	Investigation into the factors affecting accuracy of mass measurements on a time-of-flight mass spectrometer using Design of Experiment. Rapid Communications in Mass Spectrometry, 2007, 21, 529-535.	0.7	22
9	Selection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile. Analytical Chemistry, 2022, 94, 559-570.	3.2	21
10	Development and Validation of an in-line API Quantification Method Using AQbD Principles Based on UV-Vis Spectroscopy to Monitor and Optimise Continuous Hot Melt Extrusion Process. Pharmaceutics, 2020, 12, 150.	2.0	18
11	Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API). Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 1082-1089.	1.4	15
12	Trace level impurity method development with high \hat{s} field asymmetric waveform ion mobility spectrometry: systematic study of factors affecting the performance. Rapid Communications in Mass Spectrometry, 2009, 23, 181-193.	0.7	15
13	A risk-based statistical investigation of the quantification of polymorphic purity of a pharmaceutical candidate by solid-state 19F NMR. Analytica Chimica Acta, 2012, 712, 30-36.	2.6	14
14	Evaluating change during pharmaceutical product development and manufactureâ€"comparability and equivalence. Quality and Reliability Engineering International, 2011, 27, 629-640.	1.4	9
15	Determination of selectivity differences for basic compounds in gradient reverse phase high performance liquid chromatography under high pH conditions by partial least squares modelling. Analytica Chimica Acta, 2006, 570, 267-276.	2.6	7
16	Enhanced Approaches to the Identification, Evaluation, and Control of Impurities. Journal of Pharmaceutical Innovation, 2019, 14, 176-184.	1.1	7
17	Regulatory Highlights. Organic Process Research and Development, 2022, 26, 1029-1037.	1.3	6
18	The Delivery of Flexibility from the Application of QbD to API Development. Journal of Pharmaceutical Innovation, 2018, 13, 367-372.	1.1	5

#	Article	IF	CITATIONS
19	Avoid the perils of using rounded data. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 502-508.	1.4	4
20	Regulatory Highlights. Organic Process Research and Development, 2018, 22, 1712-1715.	1.3	2